Literature DB >> 18424733

Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions.

Paul F Robbins1, Yong F Li, Mona El-Gamil, Yangbing Zhao, Jennifer A Wargo, Zhili Zheng, Hui Xu, Richard A Morgan, Steven A Feldman, Laura A Johnson, Alan D Bennett, Steven M Dunn, Tara M Mahon, Bent K Jakobsen, Steven A Rosenberg.   

Abstract

Single and dual amino acid substitution variants were generated in the TCR CDRs of three TCRs that recognize tumor-associated Ags. Substitutions that enhance the reactivity of TCR gene-modified T cells to the cognate Ag complex were identified using a rapid RNA-based transfection system. The screening of a panel of variants of the 1G4 TCR, that recognizes a peptide corresponding to amino acid residues 157-165 of the human cancer testis Ag NY-ESO-1 (SLLMWITQC) in the context of the HLA-A*02 class I allele, resulted in the identification of single and dual CDR3alpha and CDR2beta amino acid substitutions that dramatically enhanced the specific recognition of NY-ESO-1(+)/HLA-A*02(+) tumor cell lines by TCR gene-modified CD4(+) T cells. Within this group of improved TCRs, a dual substitution in the 1G4 TCR CDR3alpha chain was identified that enhanced Ag-specific reactivity in gene-modified CD4(+) and CD8(+) T cells. Separate experiments on two distinct TCRs that recognize the MART-1 27-35 (AAGIGILTV) peptide/HLA-A*02 Ag complex characterized single amino acid substitutions in both TCRs that enhanced CD4(+) T cell Ag-specific reactivity. These results indicate that simple TCR substitution variants that enhance T cell function can be identified by rapid transfection and assay techniques, providing the means for generating potent Ag complex-specific TCR genes for use in the study of T cell interactions and in T cell adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18424733      PMCID: PMC2424230          DOI: 10.4049/jimmunol.180.9.6116

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  48 in total

1.  High-affinity, peptide-specific T cell receptors can be generated by mutations in CDR1, CDR2 or CDR3.

Authors:  Lukasz K Chlewicki; Phillip D Holler; Bridget C Monti; Matthew R Clutter; David M Kranz
Journal:  J Mol Biol       Date:  2004-12-22       Impact factor: 5.469

2.  Directed evolution of human T-cell receptors with picomolar affinities by phage display.

Authors:  Yi Li; Ruth Moysey; Peter E Molloy; Anne-Lise Vuidepot; Tara Mahon; Emma Baston; Steven Dunn; Nathaniel Liddy; Jansen Jacob; Bent K Jakobsen; Jonathan M Boulter
Journal:  Nat Biotechnol       Date:  2005-02-20       Impact factor: 54.908

3.  Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR.

Authors:  Jürgen Kuball; Frank W Schmitz; Ralf-Holger Voss; Edite Antunes Ferreira; Renate Engel; Philippe Guillaume; Susanne Strand; Pedro Romero; Christoph Huber; Linda A Sherman; Matthias Theobald
Journal:  Immunity       Date:  2005-01       Impact factor: 31.745

4.  A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection.

Authors:  Emma C Morris; Aristotle Tsallios; Gavin M Bendle; Shao-An Xue; Hans J Stauss
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-20       Impact factor: 11.205

5.  Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.

Authors:  Paul F Robbins; Mark E Dudley; John Wunderlich; Mona El-Gamil; Yong F Li; Juhua Zhou; Jianping Huang; Daniel J Powell; Steven A Rosenberg
Journal:  J Immunol       Date:  2004-12-15       Impact factor: 5.422

6.  Transfer of a TCR gene derived from a patient with a marked antitumor response conveys highly active T-cell effector functions.

Authors:  Marybeth S Hughes; Yik Y L Yu; Mark E Dudley; Zhili Zheng; Paul F Robbins; Yong Li; John Wunderlich; Robert G Hawley; Morvarid Moayeri; Steven A Rosenberg; Richard A Morgan
Journal:  Hum Gene Ther       Date:  2005-04       Impact factor: 5.695

7.  Selection of T cell clones expressing high-affinity public TCRs within Human cytomegalovirus-specific CD8 T cell responses.

Authors:  Lydie Trautmann; Marie Rimbert; Klara Echasserieau; Xavier Saulquin; Bérangère Neveu; Julie Dechanet; Vincenzo Cerundolo; Marc Bonneville
Journal:  J Immunol       Date:  2005-11-01       Impact factor: 5.422

8.  High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy.

Authors:  H J Zeh; D Perry-Lalley; M E Dudley; S A Rosenberg; J C Yang
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

9.  Structural and kinetic basis for heightened immunogenicity of T cell vaccines.

Authors:  Ji-Li Chen; Guillaume Stewart-Jones; Giovanna Bossi; Nikolai M Lissin; Linda Wooldridge; Ed Man Lik Choi; Gerhard Held; P Rod Dunbar; Robert M Esnouf; Malkit Sami; Jonathan M Boulter; Pierre Rizkallah; Christoph Renner; Andrew Sewell; P Anton van der Merwe; Bent K Jakobsen; Gillian Griffiths; E Yvonne Jones; Vincenzo Cerundolo
Journal:  J Exp Med       Date:  2005-04-18       Impact factor: 14.307

10.  Effects of complementarity determining region mutations on the affinity of an alpha/beta T cell receptor: measuring the energy associated with CD4/CD8 repertoire skewing.

Authors:  T C Manning; E A Parke; L Teyton; D M Kranz
Journal:  J Exp Med       Date:  1999-02-01       Impact factor: 14.307

View more
  159 in total

1.  TCR affinity and specificity requirements for human regulatory T-cell function.

Authors:  Gabriela Plesa; Lingjie Zheng; Andrew Medvec; Caleph B Wilson; Camila Robles-Oteiza; Nathaniel Liddy; Alan D Bennett; Jessie Gavarret; Annelise Vuidepot; Yangbing Zhao; Bruce R Blazar; Bent K Jakobsen; James L Riley
Journal:  Blood       Date:  2012-02-07       Impact factor: 22.113

2.  Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.

Authors:  Jeffrey Chou; Lilien N Voong; Christie L Mortales; Andrea M H Towlerton; Seth M Pollack; Xiaoji Chen; Cassian Yee; Paul F Robbins; Edus H Warren
Journal:  J Immunother       Date:  2012 Feb-Mar       Impact factor: 4.456

Review 3.  Immunotherapy for ovarian cancer: what's next?

Authors:  Lana E Kandalaft; Daniel J Powell; Nathan Singh; George Coukos
Journal:  J Clin Oncol       Date:  2010-11-15       Impact factor: 44.544

4.  Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.

Authors:  Edmund K Moon; Raghuveer Ranganathan; Evgeniy Eruslanov; Soyeon Kim; Kheng Newick; Shaun O'Brien; Albert Lo; Xiaojun Liu; Yangbing Zhao; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2015-08-31       Impact factor: 12.531

Review 5.  Manufacture of tumor- and virus-specific T lymphocytes for adoptive cell therapies.

Authors:  X Wang; I Rivière
Journal:  Cancer Gene Ther       Date:  2015-02-27       Impact factor: 5.987

6.  Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy.

Authors:  Christopher A Klebanoff; Joseph G Crompton; Anthony J Leonardi; Tori N Yamamoto; Smita S Chandran; Robert L Eil; Madhusudhanan Sukumar; Suman K Vodnala; Jinhui Hu; Yun Ji; David Clever; Mary A Black; Devikala Gurusamy; Michael J Kruhlak; Ping Jin; David F Stroncek; Luca Gattinoni; Steven A Feldman; Nicholas P Restifo
Journal:  JCI Insight       Date:  2017-12-07

Review 7.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

Review 8.  Advances in the development of cancer immunotherapies.

Authors:  Jianjun Gao; Chantale Bernatchez; Padmanee Sharma; Laszlo G Radvanyi; Patrick Hwu
Journal:  Trends Immunol       Date:  2012-09-30       Impact factor: 16.687

9.  Characterization of T-cell receptors directed against HLA-A*01-restricted and C*07-restricted epitopes of MAGE-A3 and MAGE-A12.

Authors:  Shigui Zhu; Benoit J Van den Eynde; Pierre G Coulie; Yong F Li; Mona El-Gamil; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2012 Nov-Dec       Impact factor: 4.456

10.  Subtle affinity-enhancing mutations in a myelin oligodendrocyte glycoprotein-specific TCR alter specificity and generate new self-reactivity.

Authors:  Akshata Udyavar; Rajshekhar Alli; Phuong Nguyen; Lesley Baker; Terrence L Geiger
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.